Latest psychedelics industry journal highlights $STIM competitive advantages ahead of adoption wave.
As companies like $CMPS and $GHRS (and $ATAI under $LLY) bring drugs to market, providers will be challenged to staff up and navigate regulatory complexity.
Through its
